<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03077555</url>
  </required_header>
  <id_info>
    <org_study_id>Si804/2016</org_study_id>
    <nct_id>NCT03077555</nct_id>
  </id_info>
  <brief_title>Ovulation and Follicular Development Associated With Mid Follicular Phase Initiation of Combined Hormonal Contraception</brief_title>
  <official_title>Ovulation and Follicular Development Associated With Mid Follicular Phase Initiation of Combined Hormonal Contraception Containing Estradiol Hemihydrate Compared to Ethinyl Estradiol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Quick starting combined oral contraception containing estradiol hemihydrate/nomegestrol
      acetate is effective to inhibit ovulation in healthy reproductive age women and
      non-inferiority to combined oral contraception containing ethinyl estradiol/gestodene.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized control, non-inferiority trial which compare the proportion of
      ovulation between two oral combined pills when delay starting the first tablet at
      mid-follicular phase of menstrual cycle in 18 - 40 year old, healthy women with prior normal
      and regular periods. Participations will be undergone trans-vaginal or trans-rectal
      ultrasonography between day 1 - 3 of menstrual period for evaluation of ovarian follicle/cyst
      (if present). Only women who have normal looking of ovaries without dominant ovarian follicle
      will be included in study-protocol. Immediately after trans-vaginal/trans-rectal ultrasound
      between day 7 - 9 of menstrual period, all participants will be randomly assigned to receive
      one pack of investigated pills (1.5 mg estradiol hemihydrate/2.5 mg nomegestrol acetate or 20
      mcg ethinyl estradiol/75 mcg gestodene) and to take the first tablet under direct observation
      by research-nurse. Participants will take one consecutive tablet at about the same time each
      day until complete pack. The next appointments will be every 2 - 3 days to monitor ovarian
      function by using Hoogland score until ovulation or follicular quiescence will be presented.
      The last visit will be about 1 week after complete pack to monitor adverse effect and safety
      through out the protocol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 21, 2017</start_date>
  <completion_date type="Actual">February 28, 2018</completion_date>
  <primary_completion_date type="Actual">February 28, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>two intervention groups</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ovulation inhibition</measure>
    <time_frame>1 month</time_frame>
    <description>comparison of ovulation inhibition effect between Zoely and Meliane ED with mid follicular phase starting</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>follicular development</measure>
    <time_frame>through study completion, an average of 1 month</time_frame>
    <description>pattern of ovarian follicular change after receive intervention</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Ovulation Inhibition</condition>
  <arm_group>
    <arm_group_label>Meliane ED</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 mcg ethinyl estradiol/70 mcg gestodene</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zoely</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.5 mg estradiol/2.5 mg nomegestrol acetate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoely</intervention_name>
    <description>quick start of combined hormonal contraception containing 1.5 mg estradiol /2.5 mg nomegestrol acetate</description>
    <arm_group_label>Zoely</arm_group_label>
    <other_name>estradiol hemihydrate combined pills</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meliane ED</intervention_name>
    <description>quick start of combined hormonal contraception containing 20 mcg ethinyl estradiol /75 mcg gestodene</description>
    <arm_group_label>Meliane ED</arm_group_label>
    <other_name>ethinyl estradiol combined pills</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy women, age 18 - 40 years

          -  prior normal and regular interval of menstruation

        Exclusion Criteria:

          -  current breast feeding women

          -  within 1 month period of child-delivery or miscarriage

          -  body mass index 30 kg/m2 or more

          -  contraindicated to use combined hormonal contraception

          -  current using other hormonal drugs that affect ovulation function
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Siriraj Hospital</name>
      <address>
        <city>Bangkok Noi</city>
        <state>Bangkok</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2017</study_first_submitted>
  <study_first_submitted_qc>March 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2017</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mahidol University</investigator_affiliation>
    <investigator_full_name>Preeyaporn Jirakittidul</investigator_full_name>
    <investigator_title>Principle investigator</investigator_title>
  </responsible_party>
  <keyword>quick starting contraception</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Undecided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

